中文 / English

Copyright: Shenzhen Kangtai biological products Limited by Share Ltd   Address: No. 6, KORUN Road, Nanshan District science and Technology Park, Shenzhen Tel:86-755-26988688
粤ICP备06026377号   Fax:86-755-26988600        Hotline:400-880-6992    Powered by

Fight against COVID-19
Page view:
Biokangtai’s COVID-19 Inactivated Vaccine Received Approval for clinical trial
PhaseI/II trial started in October
Kangtai Biological Products Co.,Ltd. recently received the approval for clinical trial (approval number: 2020L00041) issued by the National Medical Products Administration of China, and the Novel Coronavirus Inactivated Vaccine was approved for clinical trial on an emergency basis. The indication is to prevent COVID-19 caused by SARS-COV-2 infection.
The Novel Coronavirus Inactivated Vaccine (Vero cells) is suitable for people aged 3 years and above who are susceptible to coronavirus. After inoculation of the vaccine, the body can produce an immune response to prevent epidemic diseases caused by novel Coronavirus infection. 
The first phase production workshop of the vaccine has been completed, equipment installation and commissioning are in progress, the design capacity is expected to reach 100 million doses / year by the end of this year.
BioKangtai signs deal with AstraZeneca on development and industrialization of a Novel Coronavirus based on adenovirus vector 
Shenzhen Kangtai Biological Products Co.,Ltd signed a deal on 21th, August, and will produce AstraZeneca Plc's potential COVID-19 vaccine in mainland China.
The deal underscores Astra's frontrunner position in a global race to deliver an effective vaccine, given that Chinese ventures are leading at least eight of the 26 global vaccine development projects currently testing on humans.
Under the agreement BioKangtai, one of China's top vaccine makers, will ensure it has annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year.
The two companies will also explore the possibility of cooperation on the vaccine candidate in other markets, AstraZeneca said.